Lever
Lifestyle
- Regular aerobic exercise
- Weight management
- Smoking cessation
Blutwerte · Marker
Apolipoprotein A1
ApoA1 · Apo A-I
Lipide & Herz-KreislaufNüchtern erforderlich
- Einheit:
- g/L
- Abbreviation
- ApoA1
Apolipoprotein A1 quantifies the primary protein component of HDL involved in cholesterol transport.
Reference Ranges
Reference
1–1.6g/L
1
1.2
1.6
LowNormalHigh
Reference
Optimal
Unit · g/LRanges may vary slightly based on laboratory standards. Fasting is recommended.
Overview
Übersicht
Apolipoprotein A1 (ApoA1) is a major protein component of high-density lipoprotein (HDL) in plasma, playing a crucial role in lipid metabolism. It is involved in the reverse transport of cholesterol from tissues to the liver for excretion. Researchers have found that ApoA1 is a key factor in conferring atheroprotective properties to HDL, including cholesterol efflux capacity and anti-inflammatory effects. Clinically, ApoA1 levels are used as a biomarker for cardiovascular health, with low levels associated with increased risk of atherosclerotic cardiovascular disease. It is also considered a protective factor in conditions like acute-on-chronic liver failure (ACLF), where it is linked to improved short-term prognosis. In the context of athletic performance and longevity, ApoA1 is of interest due to its role in maintaining cardiovascular health and potentially influencing lipid metabolism efficiency. However, researchers observed that factors such as age, disease states, and genetic variations can alter ApoA1 levels and its functional properties, which may confound its interpretation. Fasting is generally recommended for accurate measurement, as lipid levels can be influenced by recent food intake.
Klinische Bedeutung
Reduced ApoA1 levels indicate increased cardiovascular risk and may reflect impaired lipid metabolism. Elevated levels are generally protective, associated with reduced risk of atherosclerosis.
Dynamics
Trend Interpretation
Rising Values
Progressively rising ApoA1 values suggest improved cardiovascular protection. Re-test annually to monitor trends.
Falling Values
Progressively falling ApoA1 values may indicate increased cardiovascular risk.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Genetic factors
- Regular physical activity
- High HDL cholesterol levels
- Certain medications (e.g., statins)
Cause
Low Levels
- Liver disease
- Inflammation
- Poor diet
- Sedentary lifestyle
Protocol
How to Optimize
Lever
Nutrition
- Increase omega-3 fatty acids
- Consume more fiber
- Limit saturated fats
Lever
Supplementation
- Niacin
- Omega-3 supplements
Note:
Consult a healthcare provider before starting any supplementation.
Testing Guidelines
🍽️Fasting Required
✓Not Time-Sensitive
Testing Frequency
Annually for adults at risk of cardiovascular disease
Interfering Factors
- Recent intense exercise
- Acute illness
Related Peptides & Hormones
Hdl Cholesterol
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges and optimal targets for apolipoprotein A1 (APOA1) remain debated, particularly in the context of various diseases such as HBV-related acute-on-chronic liver failure and cryoglobulinemia. Researchers have not yet established the precise confounders affecting APOA1 levels, nor the specific mechanisms by which it influences immune function and disease progression. Unanswered clinical questions include the role of APOA1 in therapeutic strategies for cardiovascular diseases and its potential as a prognostic marker across different populations.
25 Research Publications
187
Total Citations
16
Human/RCT
1.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Apolipoprotein A1 and B.
ReviewInfluence1.0
50
This article reviewed evidence suggesting that Apolipoprotein A1 (ApoA1) and Apolipoprotein B (ApoB) are more reliable indicators of vascular disease risk compared to traditional cholesterol measurements. Researchers highlighted their potential in clinical laboratory practice.
02Top
#02
Serum apolipoprotein A-I depletion is causative to silica nanoparticles-induced cardiovascular damage.
Animal
48
Researchers found that silica nanoparticles can deplete Apolipoprotein A1 (ApoA1) from the bloodstream, leading to cardiovascular damage. The study suggests that maintaining ApoA1 levels may be important for mitigating the toxic effects of nanoparticle exposure.
03Top
#03
HDLs and the pathogenesis of atherosclerosis.
Schwertani Adel, et al. · Current opinion in cardiology · 2018
Review
18
Researchers reviewed the role of HDL cholesterol in cardiovascular health, noting that while it serves as a biomarker, its therapeutic modulation has not proven effective in preventing atherosclerosis. The study emphasized that HDL's beneficial properties can diminish in disease states.
Key findings
- 01Researchers observed that HDL cholesterol levels are not effective therapeutic targets for preventing heart disease.
- 02They found that HDL performs various protective functions against atherosclerosis that are independent of cholesterol levels.
- 03The study identified a protein, desmocollin 1, that may hinder HDL's beneficial roles in heart health.
04
#04
HDL Structure.
Review
15
This study examined the structure and components of high-density lipoprotein (HDL), highlighting the role of Apolipoprotein A1 (Apo A-I) as a key protein involved in HDL function. Researchers found that HDL is crucial in various physiological processes, and its structural features can change in different health conditions.
05
#05
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.
Human
11
Researchers found that higher levels of Apolipoprotein A1 (ApoA1) and HDL cholesterol were associated with improved responses to immunotherapy in nasopharyngeal carcinoma patients. The study suggested that ApoA1 mimetics could enhance therapeutic outcomes by modulating macrophage polarization.
06
#06
APOA1 mRNA and serum APOA1 protein as diagnostic and prognostic biomarkers in gastric cancer.
Human
8
This study identified Apolipoprotein A1 (APOA1) as a potential prognostic biomarker in gastric cancer, showing that lower serum levels correlated with poor outcomes. Researchers emphasized the role of lipid metabolism alterations in tumor progression.
07
#07
Association between serum apolipoprotein B and atrial fibrillation: a case-control study.
Human
8
This study examined the association between Apolipoprotein B (ApoB) levels and atrial fibrillation (AF). Researchers found that lower ApoB levels were linked to a protective effect against AF in both men and women, indicating its potential as a biomarker.
08
#08
Levels and clinical significance of the m6A methyltransferase METTL14 in patients with coronary heart disease.
Human
7
This study examined the relationship between METTL14 expression and coronary heart disease (CHD). Researchers found that higher METTL14 levels were associated with increased inflammatory markers and could independently predict CHD risk.
09
#09
The common apolipoprotein A-1 polymorphism -75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction.
Human
6
Researchers found that a common polymorphism in the Apolipoprotein A1 gene is associated with an increased risk of recurrent coronary events in Black patients post-myocardial infarction. This suggests ethnic differences in genetic risk factors for coronary artery disease.
10
#10
Cholesterol metabolism-related genes predict immune infiltration and prognosis in gastric cancer patients.
HumanInfluence1.0
3
This study identified cholesterol metabolism-related genes, including Apolipoprotein A1 (ApoA1), as independent prognostic factors in gastric cancer. Researchers found that these genes could predict patient outcomes and immune cell variations, highlighting their significance in cancer treatment.
Publication Trend
Research publications about Apolipoprotein A1 over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer